Biotech’s new chief lobbyist says she’s a social justice advocate. Will the industry walk the walk?
WASHINGTON — Michelle McMurry-Heath doesn’t talk about biotech the way her peers do.
Where other executives and experts might bring up “access,” and “reimbursement,” McMurry-Heath talks about fairness and ethics.
